<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04601766</url>
  </required_header>
  <id_info>
    <org_study_id>YHGT-PN-01</org_study_id>
    <nct_id>NCT04601766</nct_id>
  </id_info>
  <brief_title>A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets</brief_title>
  <official_title>A Phase I, Open-Label, Randomized, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets 2, APL1501 ER Tablets 3, and APL-1202 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asieris Pharmaceuticals (AUS) Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Yahong Meditech Co., Ltd aka Asieris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-phase study design will be used for this pilot study. In the first phase, a 2×2&#xD;
      crossover study will be used to evaluate the safety, tolerability and PK characteristic of&#xD;
      APL-1202 and APL-1501 ER Tablets 3. Twelve healthy subjects will be in ratio 1:1 randomly&#xD;
      assigned to two groups, randomization will be stratified by gender (male, female) in ratio&#xD;
      1:1. Each group will be dosed with APL-1202, APL-1501 ER Tablets 3 in a cross-over way. A&#xD;
      7-day (±1 day) washout will be required before next period of drug administration. The&#xD;
      samples in first phase will be sent to bioanalysis lab for PK research at the end of first&#xD;
      phase. The initiate of second phase will depend on the results of first phase within 30 days&#xD;
      and not less than 7 days after the first phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Actual">February 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 18, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AEs</measure>
    <time_frame>6 months</time_frame>
    <description>Number of subjects with AEs,</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAEs</measure>
    <time_frame>6 months</time_frame>
    <description>Number of subjects with SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters: area under the curve (AUC)</measure>
    <time_frame>6 months</time_frame>
    <description>Area under the curve (AUC) of APL-1501 ER Tablets, and APL-1202 Tablets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: maximum concentration (Cmax)</measure>
    <time_frame>6 months</time_frame>
    <description>maximum concentration (Cmax), of APL-1501 ER Tablets, and APL-1202 Tablets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: Tmax</measure>
    <time_frame>6 months</time_frame>
    <description>Tmax of APL-1501 ER Tablets, and APL-1202 Tablets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: half-life</measure>
    <time_frame>6 months</time_frame>
    <description>apparent t1/2 of APL-1501 ER Tablets, and APL-1202 Tablets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine concentration</measure>
    <time_frame>6 months</time_frame>
    <description>Urine concentration of APL-1501 ER Tablets 2, APL-1501 ER Tablets 3, and APL-1202 Tablets.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulated excretion rate (Ae%)</measure>
    <time_frame>6 months</time_frame>
    <description>Accumulated excretion rate (Ae%) of APL-1501 ER Tablets 2, APL-1501 ER Tablets 3, and APL-1202 Tablets.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2</intervention_name>
    <description>Phase1: Period 1 drug administration( APL-1202 50 mg, 3 tablets, orally );Washout( 7± 1 day) ; Period 2 drug administration(1501 ER Tablets 3 382 mg ASN-1324, 1 tablet); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2</intervention_name>
    <description>Phase1: Period 1 drug administration( 1501 ER Tablets 3 382 mg ASN-1324, 1 tablet );Washout( 7± 1 day) ; Period 2 drug administration(APL-1202 50 mg, 3 tablets, orally); Phase2:Washout(The initiation of second phase will depend on the results of first phase within 30 days and not less than 7 days after the first phase ); Period 3 (APL-1501 ER Tablets 2,382 mg ASN-1324, 1 tablet)</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The subject must have informed consent before the trial, and have a full understanding&#xD;
             of the content, process and possible adverse reactions of the trial, and voluntarily&#xD;
             signed a written informed consent form&#xD;
&#xD;
          2. The subject is able to communicate well with the researchers and is able to complete&#xD;
             the trial in accordance with the protocol&#xD;
&#xD;
          3. 18 to 45 years old (including 18 and 45 years old)&#xD;
&#xD;
          4. Postmenopausal females or sterilized participant must be at least 6 months&#xD;
             post-menopausal, surgically sterile; the postmenopausal/sterilization should be&#xD;
             confirmed by FSH testing&#xD;
&#xD;
          5. The body weight of male subjects are ≥ 50 kg, and that of female subjects are ≥ 45 kg,&#xD;
             and the body mass index (BMI) are between 18.0 and 30.0 kg/m2, including the boundary&#xD;
             value. BMI= weight (kg) / height2 (m2)&#xD;
&#xD;
          6. Must have normal organ functions, including the following:&#xD;
&#xD;
               1. Bone marrow reserve: within normal range or deemed NCS by the treating&#xD;
                  investigator&#xD;
&#xD;
               2. Hepatic: total bilirubin within normal range or deemed NCS by the treating&#xD;
                  investigator; aspartate transaminase (AST) and/or alanine aminotransferase (ALT)&#xD;
                  ≤ 1.5x ULN&#xD;
&#xD;
               3. Renal: serum creatinine ≤ ULN Confidential Page 7 of 61&#xD;
&#xD;
               4. Prothrombin time (PT) and partial thromboplastin time (PTT) ≤ ULN or deemed NCS&#xD;
                  by the treating investigator&#xD;
&#xD;
               5. QTCF≤450 msec for males and 470 msec for females&#xD;
&#xD;
          7. Healthy as determined by physician, based on a medical evaluation including Physical&#xD;
             examination and vital signs, hematology, biochemistry, coagulation, urinalysis, and&#xD;
             12-lead Electrocardiograms (ECGs)&#xD;
&#xD;
          8. Willingness for subjects of reproductive potential to use highly effective methods of&#xD;
             contraception from the beginning of the study screening to the end of study follow up&#xD;
             period a. A highly effective method of contraception is defined as one that results in&#xD;
             a low failure rate (i.e., less than 1% per year, when used consistently and correctly)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to any research drug components, similar drugs or their excipients&#xD;
&#xD;
          2. History of optic nerve disorder, malignancy, anemia or gastrointestinal, liver and&#xD;
             kidney diseases that may affect the pharmacokinetics of the investigational drugs&#xD;
&#xD;
          3. Subject who is positive in one or more of the tests of hepatitis B surface antigen&#xD;
             (HBsAg), hepatitis C antibody (HCV), and AIDS antibody (HIV)&#xD;
&#xD;
          4. Subject who is positive for urine drug screening or who with a history of drug abuse&#xD;
&#xD;
          5. Subject who smoked more than 5 cigarettes per day in the 3 months before the trial,&#xD;
             and/or disagreed to avoid using any tobacco products 24 hours before administration&#xD;
             and during hospitalization&#xD;
&#xD;
          6. Regular drinkers within 6 months before the trial, that is, those who drank more than&#xD;
             14 units of alcohol per week (1 unit = 10 g pure alcohol), and/or those who do not&#xD;
             agree to stop alcohol intake 24 hours before administration and during&#xD;
             hospitalization, and/or positive in breath alcohol test. STANDARD DRINK= Volume of&#xD;
             Alcoholic Drinks x Concentration of Alcoholic Drinks x 0.789/pure alcohol&#xD;
&#xD;
          7. Systemic treatment on any investigational clinical trial within 28 days (or 5&#xD;
             half-lives of that agent, whichever is greater) prior to enrollment&#xD;
&#xD;
          8. Subject who take strong inducers or inhibitors of metabolism enzymes or transporter&#xD;
             within 48 h before the study, including but not limited to caffeine, xanthine,&#xD;
             grapefruit, grapefruit juice or grapefruit-related citrus fruits (e.g. Seville&#xD;
             oranges, pomelos) etc.&#xD;
&#xD;
          9. Pregnancy or lactation&#xD;
&#xD;
         10. Any other reason that in the opinion of the Investigator or Sponsor would prevent the&#xD;
             patient from completing participation or following the study schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scientia clinical research</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

